摘要
报告常规剂量联合方案治疗病危骨髓增生异常综合征及其继发白血病20例，完全缓解率45．0％，部分缓解率5．0％，总有效率50．0％、用小剂量阿精胞对治疗高危骨髓增生异常综合征20例，完全缓解率25．0％，部分缓解率20．0％，总有效节45．0％。二组骨髓增生异常综合征患者疗效之间比较差异不明显（P＞0．05）。对年轻高危骨髓增生异常综合征患者采用常规剂量联合化疗，在延长病人生存期和提高生存质量上都具有重要临床意义。
We reported 10 high danger myelodysplastic syndromes (MDS)and 10 its secondary acute myeloia leukemias patients with ordinary dose Combination chemotherapy. The Complete remission rate was 45. 0%, the partial remission rate was 5.0%, all effective rate ordinary dose of combination chemotherapy was 50.0%. 20 high danger MDS were treated with smell dosage Ara-C, the complete remission rate was 25. 0%, the partial remission rate was 20.0%, all effective rate was 45.0%. The curative effect of the MDS patients in between two groups were the same, P>0. 05. The patients Of the younger and high danger MDS haved been treated with ordinary dose combination chemotherapy, the important clinical signifi cances were in extening survived term and improving survived quality of MDS pa tients.
出处
《临床血液学杂志》
CAS
1998年第1期16-18,共3页
Journal of Clinical Hematology
关键词
骨髓增生异常
综合征
白血病
药物疗法
Myelodysplastic Syndrome Secondary acute myeloid leukemia
